Delayed esophagectomy for adenocarcinoma is associated with a negative impact on long‐term survival and an increased risk of perioperative morbidity

Abstract

AbstractObjectiveDelayed esophagectomy (DE) following chemoradiation therapy (CXRT) for esophageal carcinoma is undertaken in selected patients. This study aimed to assess both short‐term outcomes and long‐term survival for patients with adenocarcinoma undergoing DE.MethodsThe National Cancer Database was queried for patients with American Joint Committee on Cancer clinical stage II–III esophageal adenocarcinoma undergoing esophagectomy after CXRT. Patients were categorized as (1) DE, ≥90 days between completion of CXRT and surgery or (2) nondelayed esophagectomy (NDE), <90 days. Cox regression was performed to identify factors associated with mortality.ResultsA total of 8157 patients met criteria. Age >69, nonwhite race, Medicare/Medicaid insured patients preferentially underwent DE. Five‐year overall survival (OS) favored NDE (36% vs. 31%, p = 0.008). Cox regression identified DE, clinical stage >T2, or >N0 as factors associated with mortality. Within the DE group, OS favored early cT‐status. DE fared worse than NDE in 30‐ and 90‐day mortality (4.5%/11.1% vs. 2.9%/6.5%, p < 0.01/p < 0.001) and margin positive resection (7.1% vs. 4.2%, p < 0.001).ConclusionsFor esophageal adenocarcinoma, DE is associated with decreased OS compared to NDE. For DE, cT‐status is prognostic for OS, while cN‐status was not. Increased 30‐/90‐day mortality and margin positive resection rates for DE question whether patients with locally advanced (cT3/T4) primary esophageal adenocarcinoma should undergo intentional DE.